# Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee

> **NCT00819572** · PHASE1,PHASE2 · COMPLETED · sponsor: **ESBATech AG** · enrollment: 27 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **BIOLOGICAL:** DLX105, a single-chain (scFv) antibody fragment against TNF-alpha
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00819572
- **Lead sponsor:** ESBATech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2010-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819572, "Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00819572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*